New Insights into Cardiometabolic Diseases, 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 1878

Special Issue Editors


E-Mail Website
Guest Editor
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
Interests: metabolic diseases; hypertension; obesity type-2 diabetes; vascular diseases; thrombosis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. UND Life Sciences, 2221 NW 5th St, Battle Ground, WA 98604, USA
2. Department of Biotechnology, Indian Institute of Technology-Hyderabad, Sangareddy 502285, India
Interests: polyunsaturated fatty acids; inflammation; lipoxins; immunology; endocrinology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Following a very successful first run, we are pleased to announce the launch of a second edition of this Special Issue on “New Insights into Cardiometabolic Diseases, 2nd Edition”.

Metabolic diseases, such as hypertension, excess weight, obesity, type 2 diabetes, and vascular conditions, have become a global epidemic. These diseases are driven by metabolic risks like oxidative stress, chronic inflammation, insulin resistance, glucose intolerance, altered blood flow patterns, arterial hardening, endothelial dysfunction, and subclinical atherosclerosis. Together, these metabolic abnormalities significantly contribute to the development of metabolic diseases, accelerating the progression to acute vascular events such as heart attacks and strokes. Despite extensive efforts, no country has succeeded in reducing, reversing, or preventing these metabolic diseases. To address this critical health challenge, there is a need to delve into the cellular and molecular mechanisms that initiate metabolic risks, promote the development of these diseases, and precipitate acute vascular events. This understanding is essential for the development of early diagnostic tools, improved risk management strategies, and innovative prevention methods. To advance our knowledge in this field, we are dedicating a Special Issue to "Cardiometabolic Diseases." This Special Issue aims to create an up-to-date digital health knowledge repository, essentially serving as an encyclopedia covering all aspects of metabolic dysfunctions, ultimately contributing to progress in the management of metabolic and vascular diseases. We invite contributors to provide insights into the cellular and molecular mechanisms involved in the progression of these diseases; propose robust strategies for the early diagnosis of the risks and managing the risk factors that contribute to these diseases; and propose novel strategies for primary prevention.

Prof. Dr. Gundu H. R. Rao
Dr. Undurti N. Das
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic diseases
  • hypertension
  • obesity
  • type-2 diabetes
  • vascular diseases
  • acute vascular events

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 708 KB  
Review
Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension
by Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, Weronika Jędraszak, Gabriela Majchrowicz, Filip Prusinowski, Magdalena Stabrawa, Jacek Rysz and Beata Franczyk
Biomolecules 2025, 15(10), 1439; https://doi.org/10.3390/biom15101439 - 11 Oct 2025
Viewed by 1261
Abstract
Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the [...] Read more.
Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the CYP11B2 enzyme, responsible for aldosterone synthesis, without affecting cortisol production. This selectivity minimizes hormonal side effects. Clinical trials have shown that baxdrostat reduces plasma aldosterone in a dose-dependent manner while preserving cortisol levels. In the Phase 2 BrigHTN trial, baxdrostat significantly lowered systolic and diastolic blood pressure in patients with RH, with the 2 mg dose showing the most consistent efficacy. However, in the HALO trial, similar blood pressure reductions were observed in the placebo group, possibly due to improved adherence to background antihypertensive therapy. Baxdrostat has demonstrated a favorable safety profile, with mostly mild adverse effects and no significant impact on kidney function. It is considered safe for use with other medications, including metformin. Ongoing trials are investigating its potential in patients with chronic kidney disease (CKD) and primary hyperaldosteronism (PA). Baxdrostat represents a promising therapeutic option for aldosterone-driven hypertension, especially in patients unresponsive to standard treatments. Full article
(This article belongs to the Special Issue New Insights into Cardiometabolic Diseases, 2nd Edition)
Show Figures

Figure 1

Back to TopTop